Empagliflozin vs Zibotentan + Dapagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT03594110 · Phase 3 · completed
Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).
Next expected readout: December 2026 · NCT05786443 (registry estimate)
Reported efficacy
Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)
Result source: NCT03594110
Zibotentan + Dapagliflozin
Developed by AstraZeneca
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT06087835 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Empagliflozin | Zibotentan + Dapagliflozin |
|---|---|---|
| Kidney composite outcome | 6.1% vs 8.1%−2 vs placeboNCT035941101 other result
| —Trial running · NCT06087835 |
| UACR, % change | -39.1% vs -2.6%−36.5 vs placeboNCT051828405 other results
| —Trial running · NCT06087835 |
| eGFR slope | —Not posted · NCT05373680 | —Trial running · NCT06087835 |
| Haemoglobin, change | —Not posted · NCT05373680 | —Trial running · NCT06087835 |
Kidney composite outcome
- Empagliflozin
- 6.1% vs 8.1%−2 vs placeboNCT03594110
1 other result
- 7.5% vs 8.9% NCT03594110
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
UACR, % change
- Empagliflozin
- -39.1% vs -2.6%−36.5 vs placeboNCT05182840
5 other results
- -36.6% vs -2.6% NCT05182840
- -22.4% vs -2.6% NCT05182840
- -19% vs -10.6% NCT05182840
- -45.9% vs -10.6% NCT05182840
- -40.3% vs -10.6% NCT05182840
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
eGFR slope
- Empagliflozin
- —Not posted · NCT05373680
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
Haemoglobin, change
- Empagliflozin
- —Not posted · NCT05373680
- Zibotentan + Dapagliflozin
- —Trial running · NCT06087835
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zibotentan + Dapagliflozin: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Empagliflozin: 4 of 4 rows · Zibotentan + Dapagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Empagliflozin |
|---|---|
| Dropout rate | 22.9%10 mga NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 7.2%10 mga NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33%10 mga NCT03594110 · Phase 3 show 9 more results6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT05182840 · Phase 2 · registry result, not featured evidence 8.3%20 mg NCT05182840 · Phase 2 · registry result, not featured evidence 9.6%10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 6.8%10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 5.3%10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 4.3%3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 8 more resultsnasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 10 mg glomerular filtration rate decreased 9.9% (placebo 4.1%) hyperkalaemia 9.9% (placebo 5.5%) cortisol decreased 5.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence 20 mg hyperkalaemia 23.6% (placebo 5.5%) glomerular filtration rate decreased 8.3% (placebo 4.1%) upper respiratory tract infection 4.2% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence 10 mg + 10 mg hyperkalaemia 15.1% (placebo 5.5%) glomerular filtration rate decreased 11% (placebo 4.1%) hypotension 5.5% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 20 mg glomerular filtration rate decreased 9.5% (placebo 4.1%) hyperkalaemia 9.5% (placebo 5.5%) upper respiratory tract infection 5.4% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 3 mg hyperkalaemia 6.6% (placebo 5.5%) glomerular filtration rate decreased 5.3% (placebo 4.1%) cortisol decreased 2.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 3 mg hyperkalaemia 11.4% (placebo 5.5%) cortisol decreased 4.3% (placebo 0%) upper respiratory tract infection 2.9% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Empagliflozin
show 1 more result
show 1 more result
show 2 more results
show 5 more results
show 5 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Zibotentan + Dapagliflozin's landscape